The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients 
with previously treated non-small cell lung cancer with KRASG12C mutations. In a 
phase II trial, the drug yielded a median progression-free survival of 6.8 
months in patients whose disease had advanced despite treatment with standard 
therapies, namely platinum-based chemotherapy and PD-1-PD-L1 inhibitors.